Inditel MX 50 Tablet ER is a combination antihypertensive medication containing Telmisartan 40 mg and Metoprolol Succinate 50 mg. Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure. Metoprolol Succinate is a cardioselective beta-1 adrenergic receptor blocker that reduces heart rate, myocardial contractility, and cardiac output, contributing to blood pressure reduction and improved cardiac function. The extended-release formulation ensures a sustained therapeutic effect, allowing once-daily dosing and improved patient compliance. Inditel MX 50 is indicated for the management of hypertension, particularly in patients requiring combination therapy to achieve optimal blood pressure control. It may also be beneficial in patients with concomitant ischemic heart disease or heart failure where beta-blockade is indicated. The combination of Telmisartan and Metoprolol provides complementary mechanisms to effectively lower blood pressure and reduce cardiovascular risk. Caution is advised in patients with bradycardia, heart block, or severe hepatic impairment. Common adverse effects may include dizziness, fatigue, and hypotension. Regular monitoring of blood pressure, heart rate, and renal function is recommended during therapy. Inditel MX 50 should be used under medical supervision with appropriate dose adjustments based on clinical response.